As of May 04
| +0.31 / +0.88%|
The 6 analysts offering 12-month price forecasts for Enanta Pharmaceuticals Inc have a median target of 41.50, with a high estimate of 47.00 and a low estimate of 35.00. The median estimate represents a +17.17% increase from the last price of 35.42.
The current consensus among 7 polled investment analysts is to Buy stock in Enanta Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.